Canadian Innovations, Science and Leadership take on COVID-19

biotech ecosystem SERvice, Equipment & SuppLy Registry

The COVID-19 virus has had a remarkable impact on the industry.  While some companies are trying to ramp up work beyond their usual capacity, others are idling activity until the world returns to some form of normalcy. As a result, some companies are strained to do the work they need to do (particularly those working on COVID-19 related projects) while others have valuable equipment, labs and expertise on hold. In this context, BIOTECanada is using its national reach as a platform to connect capacity, expertise, solutions and support by bringing together those who have with those who are looking. The link below will provide an evergreen list of availability and needs across the country. We encourage you to check on the link frequently and to let us know if your company is looking for or able to provide a specific product, service or expertise. Please contact Emily Meyers to add to the registry or for more information. Registry

Canada’s history of innovation in biotechnology stretches back a century. From the discovery of insulin to the development of an Ebola vaccine, Canadian scientists, researchers and innovators have contributed to the betterment of life for Canadians and the world more broadly. Canadian researchers discovered stem cells and the Cystic Fibrosis gene, developed canola and created a non-browning apple. Building on this, there are several Canadian biotech companies currently engaged in trying to develop solutions for the COVID-19 pandemic. This space will be dedicated to showcasing the innovations and leadership emerging from the Canadian biotech ecosystem.

Canadian clinical trials

Health Canada is closely tracking all potential therapeutic treatments and vaccines in development. The Department is working with vaccine developers, researchers, and manufacturers to help expedite the development and availability of medical products such as vaccines, antibodies, and drugs to prevent and treat COVID-19.

vaccine industry collaborations

Vaccine industry leaders are working closely with all levels of government, the research community and public agencies to develop solutions to address our current and future Canadian vaccine supply needs. As an industry, we are committed to dedicating and sharing our scientific expertise, technical skills and manufacturing capabilities to address this unprecedented global health crisis. Learn more. 

on the horizon

Vital research for everything from better understanding how this virus spreads to developing vaccines and treatments. There are research teams around the world focused on developing and implementing measures to detect, manage and reduce the spread of COVID-19. Below are a few examples.

PROVINCIAL CONNECTIONS

Life Sciences British Columbia BioAlberta Ag West Bio Biosciences Association Manitoba
Life Sciences Ontario Bio Quebec BioNB BioNova
PEI BioAlliance NATI

useful links

There is an overwhelming amount of information globally available regarding COVID-19. Below you will find a collection of resources we hope you find timely and accurate.

WHO Health Canada MaRS
Fierce Biotech BioWorld Vaccine development and manufacturing in Canada

Knowledge CEntre

During this unprecedented time BIOTECanada is sharing with you some insight from its service provider members who are working with clients to navigate the business realities of the current COVID-19 situation, and the new environment which will emerge.

Employer strategies for managing novel coronavirus risks in the workplace  (BLG)
COVID-19 Legal Perspectives: Workplace issues (webinar)  (BLG)
Details on Blanket Relief for Market Participants Due to COVID-19  (Gowling WLG)
COVID-19 and Your Business (webinar)  (Gowling WLG)
Orchestrating the recovery of organizations and supply chains  (Deloitte)
Managing cash flow during a period of crisis  (Deloitte)
10 tips to manage environmental risk during uncertain times  (Norton Rose Fulbright)
Unprecedented layoffs during a global pandemic  (Norton Rose Fulbright)
COVID-19 Toolkit for private life science companies  (WSGR)
COVID-19 Update: Guidance and Practical Considerations for Virtual Annual Meetings  (WSGR)
Proactive Planning during a Global Pandemic  (Global Public Affairs)
Best practices in communications during COVID-19  (Global Public Affairs)
Canadian Immigration Law Update  (Farris LLP)
Bill C-13 Amendments to Patent Act and Food and Drugs Act  (Pangaea)

federal action plan to mobilize industry

The Plan introduces new measures to directly support the health care system since the beginning of the outbreak. It focuses on domestic capacity building, innovative solutions, and procurement of essential supplies.

FederaL action plan to mobilize science

The Prime Minister announced support to quickly mobilize Canadian researchers and life sciences companies to support large-scale efforts towards countermeasures to combat COVID-19, including potential vaccines and treatments. The funding will be used to advance projects that are already underway by university researchers and others to respond to COVID-19, and ensure domestic supply of potential vaccines. Read more here.